Norwegian biotechnology company Hofseth BioCare Thursday completed a NOK 200 million (€18.2 million/$21.3 million) private placement as it prepared to list on the Oslo Stock Exchange's main list Oslo Bors.
The funds will be used for R&D activities, expanding production capacity, ramping up sales and marketing and other corporate purposes, the company announced in a stock exchange announcement.
The sale involved 24,691,358 shares at an offer price of NOK 8.10
